DIMA Highlights

Off-the-shelf Therapeutic Lead mAbs and Membrane Protein Nanodisc



Technology Platform & Products

DIMA Single B mAb

Development Platform

Pre-validated B Cell Libraries for Drug

Pre-validated B Cell Libraries for Drug Targets

Mammalian Cell Display Based Antibody Engineering Platform

Humanization, Caninization, Felinization, Affinity Maturation, PTM Risk Removal

Functional Evaluation Data on Different Modality Platforms

CAR-T, ADC, BsAb, etc.



Prevalidated IgG mAbs

- 5,000+ Lead mAbs Ready for Out-licensing;
- **500+** Druggable Targets;

Over 1,000 Full-length Transmembrane Proteins

- Various expression platforms selection (Nanodisc, VLP, MNP, Exosome);
- HEK293 Expression System;
- 800+ full-length multi-transmembrane proteins prepared by nanodisc;

Other Products

- 2,000+ Benchmark Biosimilar
- 1,000+ ECD Proteins
- 200+ Stable Drug Target Cell Lines
- 50+ Drug Target Positive Tissue Sections


Discovery of ADC&CAR-T Lead Molecules

. . .



- Off-the-shelf Therapeutic lead mAbs
- Prevalidated B Cell Libraries
- Pre-clinical Validation Data Package available
- Custom ADC&CAR-T Projects

Prevalidated mAbs against Popular ADC/CAR-T Targets







Scan me to view the lead mAbs list


Synthetic Nanodisc-Full length Transmembrane Proteins


- 500+ targets in stock
- Wide coverage on GPCRs, ion-channels, etc.
- Comprehensive validation
- Custom production
- Applications in Cryo-EM, small molecule drug screening, etc














rion channel 12

Cat. No. FLP100048, 12-pass Cystine/glutamate transporter



DIMA Biotechnology LLC

